Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.

30 Jan 2013

AstraZeneca, Orexo partner on OX-CLI preclinical program to treat respiratory diseases

Orexo AB announced today that the company has entered into an agreement with AstraZeneca regarding OX-CLI, a preclinical program for a potential novel treatment of respiratory diseases.

28 Jan 2013

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.

22 Jan 2013

Biophysical Society Annual Meeting to highlight innovations in medicine, physics, and more

Honeybee silk-inspired materials; a deconstruction of the Ebola virus; how microbes evolve resistance to antibiotics; and a possible connection between Alzheimer's disease and type II diabetes are just some of the intriguing topics that will be presented at the 57th Annual Meeting of the Biophysical Society (BPS).

22 Jan 2013

Ceram to develop its Controlled Release Technology for the delivery of selected AstraZeneca compounds

AstraZeneca, a global pharmaceutical company, has signed an agreement with Ceram Research Ltd, the international materials development company, for Ceram to develop its Inorganic-based Controlled Release Technology in a feasibility study for the delivery of selected AstraZeneca compounds.

18 Jan 2013

Spain approves pSivida’s ILUVIEN to treat chronic diabetic macular edema

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the Spanish Agency of Drugs and Medical Devices (Agencia Espanola de Medicamentos y Productos Sanitarios) granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

18 Jan 2013

FDA clears Sanovas’ Vas Zeppelin Smart Catheter to treat chronic pulmonary diseases, lung cancer

Sanovas Inc., a life science technology company developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that it has filed with the U.S. Food and Drug Administration for clearance of the company's Vas Zeppelin Smart Catheter for the treatment of chronic pulmonary diseases and lung cancer.

17 Jan 2013

UCLA, NanoSmart partner to develop novel cancer drug delivery platform

NanoSmart Pharmaceuticals, a private biotechnology company, has entered into a research collaboration agreement with University of California Los Angeles (UCLA) to continue the development of NanoSmart's novel drug delivery platform for the treatment of cancer and other life-threatening diseases.

17 Jan 2013

Pfizer’s Quillivant XR now available in the U.S. for treatment of ADHD

Pfizer Inc. today announced that Quillivant XR (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD).

16 Jan 2013

Wockhardt receives final FDA approval for Lamotrigine to treat epilepsy

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 25mg, 50mg, 100mg, 200mg and 300mg extended release tablets of Lamotrigine, which is used in treatment of epilepsy.

9 Jan 2013

Oramed files IND with FDA to begin ORMD-0801 Phase 2 trial for type 2 diabetes

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its orally ingested insulin candidate, ORMD-0801.

9 Jan 2013

PharmaIN receives FDA orphan-drug designation for terlipressin to treat ascites

PharmaIN Corporation and LAT Pharma LLC today announced that the US Food and Drug Administration (FDA) has granted their request for orphan-drug designation for terlipressin for the treatment of ascites due to all etiologies except for cancer.

7 Jan 2013

PSCA gene’s rs2294008 variant on T nucleotide may increase risk of bladder cancer

Patients who have inherited a specific common genetic variant develop bladder cancer tumors that strongly express a protein known as prostate stem cell antigen (PSCA), which is also expressed in many pancreatic and prostate tumors, according to research at the National Institutes of Health.

4 Jan 2013

Regenerative medicine: an interview with Christophe Dardel, President of DSM Biomedical

Regenerative medicine is a new, exciting field that is based upon the belief that the human body has the inherent power to heal itself, but in some instances it just needs a little help.

3 Jan 2013

Halozyme grants Pfizer worldwide license to develop products combining Enhanze with biologics

Halozyme Therapeutics, Inc. announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc. for the purpose of developing and commercializing products combining proprietary Pfizer biologics with Halozyme's Enhanze technology.

21 Dec 2012

Novel way to design metal organic frameworks under completely liquid-free conditions

Researchers at Aldrich Materials Science, a strategic technology initiative of Sigma-Aldrich Corporation have discovered an innovative way to design an important class of three-dimensional (3D) hybrid structures, Metal Organic Frameworks (MOFs), under completely liquid-free conditions.

20 Dec 2012

Echo Therapeutics prices underwritten public offering of 3,200,000 shares of common stock

Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the pricing of a previously announced underwritten public offering of 3,200,000 shares of its common stock, offered at a price to the public of $0.95 per share.

20 Dec 2012

Scientists succeed in organising synthetic and biological nanoparticles into crystalline materials

Scientists from Aalto University, Finland, have succeeded in organising virus particles, protein cages and nanoparticles into crystalline materials. These nanomaterials studied by the Finnish research group are important for applications in sensing, optics, electronics and drug delivery.

20 Dec 2012

Pharmalink commences Nefecon Phase IIb study in primary IgA nephropathy

Pharmalink AB, a Swedish specialty pharma company, today announces it has initiated a Phase IIb study with Nefecon (Nefigan) in patients with primary IgA nephropathy at risk of developing end-stage renal disease.

18 Dec 2012

Patheon acquires Banner Pharmacaps

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced that it has completed its acquisition of Banner Pharmacaps, a specialty pharmaceutical business dedicated to the research, development and manufacturing of unique gelatin-based dosage forms.

15 Dec 2012

Drug Delivery News and Research

Further Reading

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

AstraZeneca, Orexo partner on OX-CLI preclinical program to treat respiratory diseases

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Biophysical Society Annual Meeting to highlight innovations in medicine, physics, and more

Ceram to develop its Controlled Release Technology for the delivery of selected AstraZeneca compounds

Spain approves pSivida’s ILUVIEN to treat chronic diabetic macular edema

FDA clears Sanovas’ Vas Zeppelin Smart Catheter to treat chronic pulmonary diseases, lung cancer

UCLA, NanoSmart partner to develop novel cancer drug delivery platform

Pfizer’s Quillivant XR now available in the U.S. for treatment of ADHD

Wockhardt receives final FDA approval for Lamotrigine to treat epilepsy

Oramed files IND with FDA to begin ORMD-0801 Phase 2 trial for type 2 diabetes

PharmaIN receives FDA orphan-drug designation for terlipressin to treat ascites

PSCA gene’s rs2294008 variant on T nucleotide may increase risk of bladder cancer

Regenerative medicine: an interview with Christophe Dardel, President of DSM Biomedical

Halozyme grants Pfizer worldwide license to develop products combining Enhanze with biologics

Novel way to design metal organic frameworks under completely liquid-free conditions

Echo Therapeutics prices underwritten public offering of 3,200,000 shares of common stock

Scientists succeed in organising synthetic and biological nanoparticles into crystalline materials

Pharmalink commences Nefecon Phase IIb study in primary IgA nephropathy

Patheon acquires Banner Pharmacaps

Event guide: World ADC London eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo